# Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer

> **NCT00107094** · PHASE1 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 30 (—)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT00107094
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2007-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107094, "Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00107094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*